Elevated Endotoxin Levels in Human Intravenous Immunoglobulin Concentrates Caused by (1→3)-β-D-Glucans

References

1. 1.↵
   1. Cooper J. F.,
   2. Weary M. E.,
   3. Jordan F. T.

   The impact of non-endotoxin LAL-reactive materials on Limulus amebocyte lysate analyses. PDA J. Pharm. Sci. Technol. 1997, 51 (1), 2–6.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Ikemura K.,
   2. Ikegami K.,
   3. Shimazu T.,
   4. Yoshioka T.,
   5. Sugimoto T.

   False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J. Clin. Microbiol. 1989, 27 (9), 1965–1968.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Usami M.,
   2. Ohata A.,
   3. Horiuchi T.,
   4. Nagasawa K.,
   5. Wakabayashi T.,
   6. Tanaka S.

   Positive (1→3)-β-D-glucans in blood components and release of (1→3)-β-D-glucans from depth-type membrane filters for blood processing. Transfusion 2002, 42 (9), 1189–1195.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Bonomini V.,
   2. Coli L.,
   3. Felicianngeli G.,
   4. Nanni Costa A.,
   5. Scolari M. P.

   Long-term evaluation of synthetic and cellulosic membranes in dialysis. Int. J. Artif. Organs 1994, 17 (7), 392–398.

   OpenUrlPubMed
5. 5.↵
   Human normal immunoglobulin for intravenous administration. In European Pharmacopoeia 6.6, Council of Europe, Strasbourg Cedex, France, p 5268.
6. 6.↵
   1. Cohn E. J.,
   2. Strong L. E.,
   3. Hughes W. L.,
   4. Mulford D. J.,
   5. Ashworth J. N.,
   6. Melin M.,
   7. Taylor H. L.

   Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 1946, 68 (3), 459–475.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Williams K. L.

   Endotoxins: Pyrogens, LAL Testing and Depyrogenation, 3rd ed.; Williams K. L., Ed.; CRC Press, New York, 2007; p 191.
8. 8.↵
   Bacterial endotoxins. In European Pharmacopoeia 6.0, monograph 2.6.14, Council of Europe: Strasbourg Cedex, France, p 46.
9. 9.↵
   Bacterial endotoxin test. In Pharmacopeia of the United States of America, monograph 〈85〉, Rockville, MD.
10. 10.↵
    1. Loverock B.,
    2. Simon B.,
    3. Burgenson A.,
    4. Baines A.

    A recombinant factor C procedure for the detection of gram-negative bacterial endotoxin. Pharmacopeial Forum 2009, 35 (6), 1613–1621.

    OpenUrl
11. 11.↵
    Pyrogens. In European Pharmacopoeia 6.0, monograph 2.6.8, Council of Europe, Strasbourg Cedex, France, p 164.
12. 12.↵
    1. Twohy C. W.,
    2. Nierman M. L.,
    3. Duran A. P.,
    4. Munson T. E.

    Comparison of limulus amebocyte lysates from different manufacturers. J. Parenter. Sci. Technol. 1983, 37 (3), 93–96.

    OpenUrlPubMed
13. 13.↵
    1. McCullough K. Z.

    Variability in the LAL test. J. Parenter. Sci. Technol. 1990, 44 (1),19–21.

    OpenUrlPubMed
14. 14.↵
    1. Henne W.,
    2. Schulze H.,
    3. Pelger M.,
    4. Tretzel J.,
    5. von Sengbusch G.

    Hollow-fiber dialyzers and their pyrogenicity testing by Limulus amebocyte lysate. Artif. Organs 1984, 8 (3), 299–305.

    OpenUrlPubMed
15. 15.↵
    1. Munson T.

    Statement concerning Glucans and LAL-Reactive Material in Pharmaceutical and Medical Devices. Federal Drug Administration memorandum, 1992.
16. 16.↵
    Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Kidney Int. 1991, 40 (4), 714–719.

    OpenUrlPubMed
17. 17.↵
    1. Bonomini V.,
    2. Berland Y.,
    3. Ronco C.

    1. Mujais S. K.,
    2. Ivanovich P.,
    3. Bereza L. A.,
    4. Vidovich M.

    In Dialysis Membranes: Structure and Predictions, 113; Bonomini V., Berland Y., Ronco C., Eds.; Karger: Basel, 1995; p 101.

    OpenUrl
18. 18.↵
    1. Yoshida M.,
    2. Roth R. I.,
    3. Grunfeld C.,
    4. Feingold K. R.,
    5. Levin J.

    Soluble (1→3)-β-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J. Lab. Clin. Med. 1996, 128 (1), 103–114.

    OpenUrlPubMed
19. 19.↵
    1. Kato A.,
    2. Takita T.,
    3. Furuhashi M.,
    4. Takahashi T.,
    5. Maruyama Y.,
    6. Hishida A.

    Elevation of blood (1→3)-β-D-glucan concentrations in hemodialysis patients. Nephron 2001, 89 (1), 15–19.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Mennink-Kersten M. A.,
    2. Warris A.,
    3. Verweij P. E.

    1,3-β-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N. Engl. J. Med. 2006, 354 (26), 2834–2835.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Ascioglu S.,
    2. Rex J. H.,
    3. de Pauw B.,
    4. Bennett J. E.,
    5. Bille J.,
    6. Crokaert F.,
    7. Denning D. W.,
    8. Donnelly J. P.,
    9. Edwards J. E.,
    10. Erjavec Z.,
    11. Fiere D.,
    12. Lortholary O.,
    13. Maertens J.,
    14. Meis J. F.,
    15. Patterson T. F.,
    16. Ritter J.,
    17. Selleslag D.,
    18. Shah P. M.,
    19. Stevens D. A.,
    20. Walsh T. J.

    Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 2002, 34 (1), 7–14.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Obayashi T.,
    2. Yoshida M.,
    3. Mori T.,
    4. Goto H.,
    5. Yasuoka A.,
    6. Iwasaki H.,
    7. Teshima H.,
    8. Kohno S.,
    9. Horiuchi A.,
    10. Ito A.,
    11. et al

    . Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345 (8941), 17–20.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Ostrosky-Zeichner L.,
    2. Alexander B. D.,
    3. Kett D. H.,
    4. Vazquez J.,
    5. Pappas P. G.,
    6. Saeki F.,
    7. Ketchum P. A.,
    8. Wingard J.,
    9. Schiff R.,
    10. Tamura H.,
    11. Finkelman M. A.,
    12. Rex J. H.

    Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 2005, 41 (5), 654–659.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Odabasi Z.,
    2. Mattiuzzi G.,
    3. Estey E.,
    4. Kantarjian H.,
    5. Saeki F.,
    6. Ridge R. J.,
    7. Ketchum P. A.,
    8. Finkelman M. A.,
    9. Rex J. H.,
    10. Ostrosky-Zeichner L.

    Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 2004, 39 (2), 199–205.

    OpenUrlAbstract/FREE Full Text